Company intelligence / Profile preview

RARE Hope

Ownership: Private
Development stage: Other

Overview

Rare Hope is a biotechnology company dedicated to the discovery and development of novel therapeutics for underserved rare diseases. The company leverages advanced genomic insights and high-throughput screening to identify potential drug candidates across multiple modalities, including small molecules and gene therapies. By focusing on conditions with high unmet medical needs, Rare Hope aims to accelerate the path from laboratory research to clinical application. The organization emphasizes collaborative partnerships with patient advocacy groups and academic institutions to ensure patient-centric drug development.

Therapeutic areas: Rare Diseases
Modalities: Small moleculeGene therapy
Industry: Biotech

Beyond the preview

Go deeper on RARE Hope.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RARE Hope.

Explore the full profile